Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the
Category: Press Release
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 19, 2019– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries. “It is a pleasure to welcome Scarlett to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “Her
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
Download PDF – Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC – – Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs – – Data Featured in Oral Presentation at the 18th International Kidney Cancer Symposium – CAMBRIDGE,
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidney and other cancers,” said Michael Bailey, president and chief executive officer of AVEO.
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
Download PDF – NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – – Company Plans Final OS Analysis in 2Q20 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
Download PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well Tolerated – – Data to be Presented at the ESMO 2019 Annual Congress – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 23, 2019– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
Download PDF – 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3